<DOC>
	<DOCNO>NCT01293838</DOCNO>
	<brief_summary>The primary objective examine whether Cipralex® effective safe treatment anxiety disorder youth . The secondary objective identify change arousal stress response pre- post-treatment Cipralex® youth anxiety disorder .</brief_summary>
	<brief_title>Cipralex® Anxiety Disorders Adolescents</brief_title>
	<detailed_description>Anxiety disorder common mental illness adolescence , overall prevalence range 5.0 % 10.8 % ( Costello et al , 1996 ; Ford et al , 2003 ; Fergusson et al , 1993 ; Shaffer et al , 1996 ; Verhulst et al. , 1997 ) . Six- 12-month prevalence estimate 0.5-2.4 % separation anxiety disorder ( SAD ) , 2.1-4.6 % overanxious disorder ( OAD ) , DSM-III antecedent generalize anxiety disorder ( GAD ) , 1.7-6.9 % social phobia ( SP ) , 0.3-1.2 % panic disorder ( PD ) ( Bowen et al , 1990 ; Fergusson et al , 1993 ; Ford et al , 2003 ; Lewinsohn et al , 1993 ; Romano et al , 2001 ; Verhulst et al , 1997 ) . In US National Comorbidity Survey , median age onset anxiety disorder 11 year ( range 6-21 year ) , much young substance use disorder ( 20 year ) mood disorder ( 30 year ) ( Kessler , 2005 ) . However , anxious youth often go undiagnosed untreated , possibly tend compliant nondisruptive ( Esser et al , 1990 ) . This concern since research suggest youth untreated anxiety disorder likely develop significant problem later life , continue anxiety , depression , substance abuse , suicide attempt , educational underachievement , impaired psychosocial functioning ( Pine et al , 1998 ; Woodward &amp; Fergusson , 2001 ) . The exist literature pharmacological treatment anxiety disorder adolescent limit , suggest selective serotonin reuptake inhibitor ( SSRIs ) treatment choice pervasive impairing anxiety disorder youth ( Reinblatt &amp; Walkup , 2005 ) . A randomized control trial ( RCT ) provide support use SSRIs fluvoxamine fluoxetine treatment SAD , GAD SP . Cipralex® new SSRI whose use treatment anxiety disorder adolescent document one previous open trial ( Isolan et al. , 2007 ) . Results study RCTs conduct adult anxiety disorder suggest Cipralex® effective safe relieving symptom anxiety adolescent . Primary objective : ( 1 ) ass clinical psychosocial change associate 16-week open-label treatment Cipralex® ( 10 20 mg/day ) adolescents SAD , SP , PD and/or GAD ; ( 2 ) ass tolerance safety Cipralex® ( 10 20 mg/day 16 week ) adolescent SAD , SP , PD and/or GAD . Secondary objective : ( 1 ) investigate change physiological measure arousal stress response ( i.e. , heart rate variability , salivary concentration cortisol alpha-amylase , acoustic startle response , ) use standardized laboratory stressor , treatment Cipralex® ( 10 20 mg/day 16 week ) youth anxiety disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<criteria>Primary diagnosis ( 1 ) Social Phobia Generalized Anxiety Disorder Separation Anxiety Disorder Panic Disorder Comorbid depression allow Unstable medical condition Substance use disorder Current diagnosis OCD Lifetime diagnosis developmental delay , pervasive developmental disorder , psychosis</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Adolescents</keyword>
	<keyword>Anxiety Disorder</keyword>
	<keyword>Cipralex</keyword>
	<keyword>Social Phobia</keyword>
	<keyword>Separation Anxiety Disorder</keyword>
	<keyword>Panic Disorder</keyword>
	<keyword>Generalized Anxiety Disorder</keyword>
	<keyword>physiological arousal</keyword>
	<keyword>stress response</keyword>
	<keyword>salivary cortisol</keyword>
	<keyword>salivary alpha-amylase</keyword>
	<keyword>heart rate variability</keyword>
</DOC>